Uniqure NV
NASDAQ:QURE

Watchlist Manager
Uniqure NV Logo
Uniqure NV
NASDAQ:QURE
Watchlist
Price: 17.43 USD 2.65% Market Closed
Market Cap: 849.5m USD
Have any thoughts about
Uniqure NV?
Write Note

Uniqure NV
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Uniqure NV
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Uniqure NV
NASDAQ:QURE
Other Long-Term Assets
$12.3m
CAGR 3-Years
-17%
CAGR 5-Years
34%
CAGR 10-Years
26%
Pharming Group NV
AEX:PHARM
Other Long-Term Assets
$38.4m
CAGR 3-Years
27%
CAGR 5-Years
4%
CAGR 10-Years
69%
ProQR Therapeutics NV
NASDAQ:PRQR
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Other Long-Term Assets
$224.2m
CAGR 3-Years
133%
CAGR 5-Years
263%
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Other Long-Term Assets
$3.5m
CAGR 3-Years
9%
CAGR 5-Years
28%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Other Long-Term Assets
$319k
CAGR 3-Years
-26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Uniqure NV
Glance View

Market Cap
849.5m USD
Industry
Biotechnology

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

QURE Intrinsic Value
15.99 USD
Overvaluation 8%
Intrinsic Value
Price

See Also

What is Uniqure NV's Other Long-Term Assets?
Other Long-Term Assets
12.3m USD

Based on the financial report for Sep 30, 2024, Uniqure NV's Other Long-Term Assets amounts to 12.3m USD.

What is Uniqure NV's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
26%

Over the last year, the Other Long-Term Assets growth was -33%. The average annual Other Long-Term Assets growth rates for Uniqure NV have been -17% over the past three years , 34% over the past five years , and 26% over the past ten years .

Back to Top